Prevention of Capecitabine Induced Hand and Foot Syndrome

Cancer Clinical Trial

Official title: A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome

Status Not yet recruiting

Clinical Trial Summary

Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness and painful sores. Quite often the drug dose is reduced to suboptimal level due to this side effect. There is no way to prevent or an effective way to treat this side effect. The investigators aim is to investigate whether wearing socks which contain copper fibers may prevent or alleviate the patient symptoms.

Clinical Trial Description

Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness and painful sores. Quite often the drug dose is reduced to suboptimal level due to this side effect. There is no way to prevent or an effective way to treat this side effect. Our aim is to investigate whether wearing socks which contain copper fibers may prevent or alleviate the patient symptoms.

The patients will use socks containing copper-oxide impregnated fibers which are sold in the Pharma stores without physician's prescription.(EPA numbers 8454-2, 8454-3 from April 30 2009).

Drug Toxicity and skin reaction will be documented. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Cancer
• Hand-Foot Syndrome

• NCT number: NCT01291628
• Study type: Interventional
• Source: Rabin Medical Center
• Contact: Rinat Yerusahlmi, MD
• Phone: 972-3-8024
• Email: rinaty@clalit.org.il
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2012
• Completion date: January 2014